Consumer Services · NSE: ENTERO
Entero Healthcare Solutions
Q2 FY27 earnings and concall highlights
Q2 FY27 earnings call · Guided by management
Call held 5 Nov 2026 · Read the filing on NSEFiling
- M.Cap
- ₹8,546Cr
- P/E
- 61.3×
- 1Y return
- +75.12%
- From 52W high
- −8.1%
Highlights are read by AI from the company's filing and can contain mistakes. Check the source page linked to each line.
Share price
Results Q2 FY27, as filed · consolidated · ₹ Cr
| Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ | |
|---|---|---|---|---|---|
| Revenue | 2,087 | 1,571 | +32.9% | 1,940 | +7.6% |
| EBITDA | 111 | 62 | +78.3% | 97 | +14.1% |
| EBITDA margin | 5.3% | 4.0% | +135 bps | 5.0% | +30 bps |
| PBTProfit before tax | 78 | 45 | +75.7% | 67 | +16.8% |
| Net profit | 46 | 32 | +44.1% | 38 | +19.3% |
| EPS (₹) | 10.45 | 7.25 | +44.1% | 8.76 | +19.3% |
From the company's own results filing on NSE. Net profit is the owners' share. Growth and the dotted lines are worked out from the filed figures.
Guidance
Full-year growth and margin expected to be better than earlier guidance
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 8
Full-year growth and margin expected to be better than earlier guidance
“But, you can be rest assured that it would be better than what we had guided before, both on the growth and on the margin.”
Company will do better than guided but gives no new revenue guidance
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 5
Company will do better than guided but gives no new revenue guidance
“I am not specifically giving a new guidance right now on the call, but I can very confidently say that we will do better than what we have guided.”
Organic growth without acquisitions next year described as 'our endeavor'
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 15
Organic growth without acquisitions next year described as 'our endeavor'
“Yes, that will be our endeavor for sure. Organically also, there are many opportunities, not that all the opportunities lie in only the inorganic realm.”
More figures from the call
“MedTech, as we have guided before, it is in a range of 15%+ of our total revenues.”
“The board, internally, we have this mandate that we will not exceed 2x net debt to EBITDA ratio.”
In short
- 01Management expects to beat its FY27 guidance of about 23% revenue growth and 5% EBITDA margin.
- 02The 50% EBITDA-to-operating-cash-flow conversion guidance for FY27 is kept.
- 03Q2 revenue grew 32.9% to Rs 2,087 crore; EBITDA margin rose 135 bps to 5.3%.
- 04Net working capital days were 64 due to delayed Maharashtra government payments, since received.
- 05MedTech is 15%+ of revenue and expected to exceed Rs 1,000 crore this year.
- 06Management is evaluating acquisitions, none below Rs 100 crore, and hopes to close one this year.
- 07Trade margin caps and MRP cuts are not expected to affect margins; notified molecules are 2% of sales.
- 08A subsidiary customer default led to a provision in Other Expenses in Q2.
Segments
MedTech: Company expanding addressable market across healthcare products, particularly MedTech
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
MedTech: Company expanding addressable market across healthcare products, particularly MedTech
“We are progressively expanding our addressable market by building capabilities across the broader healthcare products ecosystem, particularly in MedTech.”
MedTech: MedTech still has product categories the company does not yet handle
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 15
MedTech: MedTech still has product categories the company does not yet handle
“MedTech, we still have a lot of other categories left. Pharma, more or less, we have covered quite a bit. But in MedTech, we still have other product categories still which we are not doing today.”
Calendarisation boost from past acquisitions to taper in Q3 and more in Q4
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 7
Calendarisation boost from past acquisitions to taper in Q3 and more in Q4
“Yes, certainly the calendarisation impact will definitely go down until and unless we announce new acquisitions, because it is going to taper off partly in quarter three and more so in quarter four.”
Demand
Indian healthcare product market expected to keep growing at double digits
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Indian healthcare product market expected to keep growing at double digits
“The Indian healthcare product market remains largely fragmented and is expected to continue growing at a healthy double-digit pace.”
Company says it continues to gain market share ahead of industry growth
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
Company says it continues to gain market share ahead of industry growth
“We continue to gain market share, outpacing industry growth.”
Organic growth from more customers, higher wallet share and new product categories
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 10
Organic growth from more customers, higher wallet share and new product categories
“It includes expansion in customer base, it includes improvement in wallet share from the customers, it includes new product categories, growth coming from new product categories.”
H1 reach: over 92,200 retail and 2,900 hospital customers in about 500 districts
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
H1 reach: over 92,200 retail and 2,900 hospital customers in about 500 districts
“In H1, we served over 92,200 retail customers and more than 2,900 hospital customers, spread in approximately 500 districts in more than 20 states and union territories”
Recent pharma market growth mostly from volume; no view on how long it lasts
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 14
Recent pharma market growth mostly from volume; no view on how long it lasts
“Most of this growth has come from volume growth rather than pricing or new product introduction. So how long is this sustainable, those kinds of growth rates? I don't have any particular view on that.”
Margins and costs
Q2 gross margin up 126 bps to 11.5%; EBITDA margin up 135 bps to 5.3%; EBITDA up 78%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
Q2 gross margin up 126 bps to 11.5%; EBITDA margin up 135 bps to 5.3%; EBITDA up 78%
“Gross margin expanded 126 basis points year-on-year to 11.5%, and EBITDA margin expanded 135 basis points to 5.3%, and EBITDA grew by 78% year-on-year.”
Margin gains from procurement scale, more MedTech revenue and exit from low-margin accounts
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
Margin gains from procurement scale, more MedTech revenue and exit from low-margin accounts
“Margin expansion was driven by three levers: scale-led procurement economies, a growing share of revenue from MedTech business, and the deliberate exit from certain low-margin accounts.”
H1 gross profit Rs 461 crore, gross margin 11.5%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
H1 gross profit Rs 461 crore, gross margin 11.5%
“Gross profit was INR461 crores, with a margin at 11.5%.”
Margins depend on value added, such as demand generation, more than on product
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 6
Margins depend on value added, such as demand generation, more than on product
“So, the margin is more dependent on the value- add that you have provided rather than by the specific product that you are selling.”
Debt and working capital
Net working capital days at 64 due to delayed government receivables in Maharashtra
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Net working capital days at 64 due to delayed government receivables in Maharashtra
“Net working capital days were at 64 days due to timing in trade receivables on certain government contracts. This was on account of funds being reallocated due to drought situation in Maharashtra.”
Delayed collection received in November; adjusted NWC days would be 61
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Delayed collection received in November; adjusted NWC days would be 61
“I would like to mention that collection has been received in November, and adjusting for that, NWC days would have been 61 days, which is similar to the previous quarter.”
Delayed Maharashtra government payment received in November was about Rs 55 crore
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 15
Delayed Maharashtra government payment received in November was about Rs 55 crore
“I think it was around INR55 crore.”
H1 operating cash outflow of Rs 46.5 crore, hit by Maharashtra fund reallocation
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
H1 operating cash outflow of Rs 46.5 crore, hit by Maharashtra fund reallocation
“Operating cash flow was negative INR46.5 crores. As I mentioned before, NWC days and consequently OCF were impacted on account of reallocation of funds by the government due to the drought situation in Maharashtra.”
H1 NWC days improved to 66 from 68; H1 EBITDA margin 5.2%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
H1 NWC days improved to 66 from 68; H1 EBITDA margin 5.2%
“EBITDA margin in first of the year was 5.2%. NWC days improved to 66 compared to 68 in the comparable period last year.”
Acquisitions and new business
Acquisition opportunities being evaluated that could close this year
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 8
Acquisition opportunities being evaluated that could close this year
“No, we are evaluating some opportunities that can be closed in this year itself.”
Large acquisitions available in pharma and MedTech; hopeful of a deal this year
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 12
Large acquisitions available in pharma and MedTech; hopeful of a deal this year
“We are evaluating opportunities there. It is not that we are not engaging with anyone or we are not looking at it. We are evaluating, and I am hopeful something will happen this year.”
Not looking at acquisitions below Rs 100 crore
₹100–0CrPrabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 12
Not looking at acquisitions below Rs 100 crore
₹100–0Cr“We are not looking at something which is lower than INR100 crore.”
Acquisition targets: portfolio expansion into new product categories or new geographies
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 8
Acquisition targets: portfolio expansion into new product categories or new geographies
“Most of the opportunities that we are evaluating are in the space either which leads to a portfolio expansion for us or in product categories that we are not dealing in today or related to new geography that we don't have much presence today.”
Management favours product expansion in acquisitions
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
Management favours product expansion in acquisitions
“Generally, we are more excited by product expansion. I can just tell you that.”
One-offs
Government contract payment delay to be treated as one-off
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 13
Government contract payment delay to be treated as one-off
“We should take that as one-off, and if we account for that, then, the NWC days or working capital days would have been the same as the previous quarter.”
Customer of a subsidiary defaulted; entire amount provided in Other Expenses
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
Customer of a subsidiary defaulted; entire amount provided in Other Expenses
“Entire amount, as we said in that note, has been provided in, regarding that receivable in our books in Other Expenses line.”
Company has legal rights to recover defaulted subsidiary receivable
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 9
Company has legal rights to recover defaulted subsidiary receivable
“Basically, the issue is about a customer default from one of our subsidiaries, a customer of one of our subsidiaries. And we have all the legal rights to go for recovery.”
Part of the default was provided earlier; a significant part in Q2
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 9
Part of the default was provided earlier; a significant part in Q2
“Not all of it. Partial part of it, because part of it was already provided before, so it is part of our opening provision balance. But yes, a significant part of it was provided in this quarter itself.”
Q2 margin would have been higher without the subsidiary receivable provision
Prabhat Agrawal · Managing Director and Chief Executive Officer · Q&A · p. 7
Q2 margin would have been higher without the subsidiary receivable provision
“Yes, the margin would have been higher, if we had not provided the amount in Q2.”
Risks
MRP revisions and trade margin cap not likely to affect company margins
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 5
MRP revisions and trade margin cap not likely to affect company margins
“Whatever MRP revisions happen, or whatever new products are being brought into the trade margin cap, okay, it is not likely to impact our margin profile as such. The reason being, we were not making those kinds of extra margins.”
137 molecules notified by NPPA are only 2% of company sales
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
137 molecules notified by NPPA are only 2% of company sales
“But when I look at my sales, these 137 molecules that has been as of now notified by NPPA, that those molecules total sales in our portfolio is only 2% as of now.”
Oncology MRP cuts expected to fall mostly on hospitals, partly manufacturers, not distributors
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 14
Oncology MRP cuts expected to fall mostly on hospitals, partly manufacturers, not distributors
“But we don't see any major or any impact coming to a distributor, because distributor anyway was not making a lot of margins in this.”
Distributor margin percentage did not change in 2019 or under past DPCO and MRP cuts
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
Distributor margin percentage did not change in 2019 or under past DPCO and MRP cuts
“Now, coming to the second one, the margin percentage did not change. It did not change in 2019. It has not changed ever from whenever the DPCO or any MRP reduction happened.”
Unknown whether manufacturers will cut prices later; little impact seen for now
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 11
Unknown whether manufacturers will cut prices later; little impact seen for now
“But, I do not know if some of it will be passed back to the company and they reduce the pricing later on. But as of now, I do not see much of an impact coming from that.”
Other
Q2 consolidated revenue grew 32.9% to Rs 2,087 crore
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
Q2 consolidated revenue grew 32.9% to Rs 2,087 crore
“Consolidated revenues grew by 32.9% to INR2,087 crores.”
Q2 organic growth was 18.2%, or 20% like-for-like
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 3
Q2 organic growth was 18.2%, or 20% like-for-like
“Organic growth was strong at 18.2% and 20% on a like-for-like basis.”
Q2 profit after tax Rs 61 crore, up 66%, PAT margin 2.9%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Q2 profit after tax Rs 61 crore, up 66%, PAT margin 2.9%
“Profit after tax for the quarter was INR61 crores, up 66% year-on-year, with a PAT margin of 2.9%.”
Q2 profit attributable to owners Rs 46 crore, up 44%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Q2 profit attributable to owners Rs 46 crore, up 44%
“Profit after tax attributable to owners was INR46 crores, up 44% year-on-year.”
Q2 ROCE 22.0% and ROE 22.4%
Prabhat Agrawal · Managing Director and Chief Executive Officer · p. 4
Q2 ROCE 22.0% and ROE 22.4%
“ROCE and ROE were 22.0% and 22.4%, respectively.”
Sources
- Earnings call transcript, Q2 FY27 Filed 12 Nov 2026 · 15 pages
Management's own statements, quoted from its NSE filings. This page was read by AI and can contain mistakes: check the source pages before relying on any figure. No forecast or opinion of ours. Not investment advice.

